Scarica l'app Stockscreener
1.18
3.28%
-0.04
Dopo l'orario di chiusura:
1.18
Panoramica
Notizia
Cronologia dei prezzi
Catena di opzioni
Financials
Perché BTAI Giù?
Forum
Previsione
Bioxcel Therapeutics Inc Borsa (BTAI) Ultime notizie
BioXcel Therapeutics Inc. (BX20.SG) Analyst insights, Price targets and Recommendations - Yahoo Finance Singapore
BTAI Should I Buy - Intellectia AI
BTAI: HC Wainwright & Co. Lowers Price Target, Maintains Buy Rat - GuruFocus
H.C. Wainwright cuts BioXcel Therapeutics price target on dilution By Investing.com - Investing.com Australia
H.C. Wainwright cuts BioXcel Therapeutics price target on dilution - Investing.com
H.C. Wainwright Maintains BioXcel Therapeutics(BTAI.US) With Buy Rating, Cuts Target Price to $5 - Moomoo
FDA accepts BioXcel filing for at-home agitation treatment By Investing.com - Investing.com South Africa
BTAI Technical Analysis & Stock Price Forecast - Intellectia AI
BioXcel Therapeutics, Inc. (BTAI) Stock Price, News, Quote & History - ca.finance.yahoo.com
BioXcel Therapeutics, Inc. (BTAI) stock price, news, quote and history - Yahoo Finance Singapore
FDA accepts BioXcel filing for at-home use of agitation drug - Investing.com Australia
BTAI: FDA Reviews BioXcel's Home Use Application for Igalmi - GuruFocus
FDA Accepts BioXcel sNDA for At-Home IGALMI Use - TipRanks
BioXcel Therapeutics Announces Food and Drug Administration Acceptance of Supplemental New Drug Application for Use of IGALMI in the At-Home Setting - MarketScreener
FDA accepts BioXcel Therapeutics application for IGALMI in at-home agitation treatment - Investing.com UK
FDA accepts BioXcel filing for at-home agitation treatment - Investing.com
BioXcel Therapeutics Announces Food & Drug Administration Acceptance of Supplemental New Drug Application for Use of IGALMI® in the At-Home Setting - The Manila Times
BioXcel seeks first at-home FDA-approved agitation treatment - Stock Titan
BioXcel Therapeutics (BTAI) gets FDA review date for IGALMI at-home agitation use - Stock Titan
BTAI.O Forecast — Price Prediction for 2026. Should I Buy BTAI.O? - Intellectia AI
BTAI.O PE Ratio & Valuation, Is BTAI.O Overvalued - Intellectia AI
BTAI.O Technical Analysis & Stock Price Forecast - Intellectia AI
BioXcel Therapeutics Announces Food & Drug Administration Acceptance of Supplemental New Drug Application for Use of IGALMI in the At-Home Setting - Bitget
Certain Common Stock of BioXcel Therapeutics, Inc. are subject to a Lock-Up Agreement Ending on 1-APR-2026. - MarketScreener
Certain Warrants of BioXcel Therapeutics, Inc. are subject to a Lock-Up Agreement Ending on 1-APR-2026. - MarketScreener
BTAI SEC FilingsBioxcel Therapeutics Inc 10-K, 10-Q, 8-K Forms - Stock Titan
Why are BioXcel Therapeutics shares down Friday? - MSN
Bank of America Securities Remains a Sell on Bioxcel Therapeutics (BTAI) - The Globe and Mail
Qatar Investment Authority (BTAI) reports 156,066 BioXcel shares owned - Stock Titan
Pharvaris (NASDAQ:PHVS) versus BioXcel Therapeutics (NASDAQ:BTAI) Critical Comparison - Defense World
Free cash flow per share of BioXcel Therapeutics, Inc. – FWB:BX20 - TradingView
How The BioXcel Therapeutics (BTAI) Story Is Shifting With BXCL501 Hopes And Dilution Risks - Yahoo Finance
SHAREHOLDER ALERT: Potential Recovery for BioXcel Therapeutics, Inc. (BTAI) Investors Affected by Stock Drop – Levi & Korsinsky Pursuing Class Action Lawsuit - ACCESS Newswire
BioXcel Therapeutics, Inc. 2025 Annual Report Highlights: Business Overview, Risk Factors, and Forward-Looking Statements - Minichart
BioXcel Therapeutics Inc. R (BX20.F) Analyst Ratings, Estimates & Forecasts - Yahoo! Finance Canada
BioXcel Therapeutics (NASDAQ: BTAI) bets on BXCL501 at-home use - stocktitan.net
BioXcel Therapeutics, Inc. Reports Earnings Results for the Full Year Ended December 31, 2025 - MarketScreener
BioXcel Therapeutics Inc reports results for the quarter ended December 31Earnings Summary - TradingView
BioXcel Therapeutics reports Q4 & FY2025 results; FY revenue $642k, net loss $69.9M - TradingView
BTAI: IGALMI at-home sNDA submitted; revenue down, cost controls in place, large market targeted - TradingView
BioXcel (NASDAQ: BTAI) flags going concern as IGALMI label bid advances - Stock Titan
AI-driven biopharma firm BioXcel Therapeutics posts lower-than-expected Q4 loss on reduced SG&A costs - TradingView
Earnings Scheduled For March 27, 2026 - Benzinga
BRIEF-BioXcel Therapeutics Q4 Basic EPS USD -0.58 Vs. IBES Estimate USD -0.75 - TradingView
BioXcel Therapeutics Reports Fourth Quarter and Full-Year 2025 Financial Results as Company Prepares for Potential IGALMI® Approval in Outpatient Setting - ChartMill
ETF Watch: Is BioXcel Therapeutics Inc benefiting from interest rate changes2026 Highlights & Target Return Focused Picks - baoquankhu1.vn
BioXcel Therapeutics $9.75M Class Action Settlement - Claim Depot
Levi & Korsinsky, LLP Announces Proposed Class Action Settlement on Behalf of Purchasers of BioXcel Therapeutics, Inc. - GlobeNewswire Inc.
Why did BTAI stock surge 20% in pre-market today? - MSN
If You Invested $1,000 in Bioxcel Therapeutics Inc (BTAI) - Stock Titan
Stock Ratings | Baird Bank raises CRCL's price target to $138; Rodman & Renshaw initiates coverage of BTAI with a "buy" recommendation and a $17 price target, representing a potential upside of 882.66%. - Sahm
Buyout Rumor: Whats BioXcel Therapeutics Incs historical return2026 Trade Ideas & High Accuracy Swing Entry Alerts - baoquankhu1.vn
BioXcel Therapeutics Inc (BTAI) Stock Price, Quote, News & History - Benzinga
BioXcel Therapeutics stock initiated with buy rating at Rodman By Investing.com - ca.investing.com
1.11%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):